Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma (Nasdaq: RPRX) has awarded its inaugural Prize for Impact in Healthcare to Michael Milken, founder of the Milken Institute, Faster Cures, and the Prostate Cancer Foundation. The prize includes a $250,000 charitable donation to support medical research initiatives. Milken's Prostate Cancer Foundation has raised over $1 billion since 1993, supporting 2,240 research projects across 245 cancer centers in 28 countries, leading to FDA approval of six new drugs for advanced prostate cancer. The foundation's work has contributed to declining prostate cancer mortality rates over the past two decades.
Royalty Pharma (Nasdaq: RPRX) ha assegnato il suo primo Premio per l'Impatto nella Salute a Michael Milken, fondatore del Milken Institute, di Faster Cures e della Prostate Cancer Foundation. Il premio include una donazione caritativa di $250.000 per sostenere iniziative di ricerca medica. La Prostate Cancer Foundation di Milken ha raccolto oltre 1 miliardo di dollari dal 1993, sostenendo 2.240 progetti di ricerca in 245 centri oncologici in 28 paesi, portando all'approvazione da parte della FDA di sei nuovi farmaci per il carcinoma prostatico avanzato. Il lavoro della fondazione ha contribuito alla diminuzione dei tassi di mortalità per cancro alla prostata negli ultimi due decenni.
Royalty Pharma (Nasdaq: RPRX) ha otorgado su primer Premio por el Impacto en la Salud a Michael Milken, fundador del Milken Institute, Faster Cures y la Prostate Cancer Foundation. El premio incluye una donación benéfica de $250,000 para apoyar iniciativas de investigación médica. La Prostate Cancer Foundation de Milken ha recaudado más de 1 mil millones de dólares desde 1993, apoyando 2,240 proyectos de investigación en 245 centros contra el cáncer en 28 países, lo que ha llevado a la aprobación de seis nuevos medicamentos para el cáncer de próstata avanzado por parte de la FDA. El trabajo de la fundación ha contribuido a la disminución de las tasas de mortalidad por cáncer de próstata en las últimas dos décadas.
로열티 파마 (Nasdaq: RPRX)는 마이클 밀켄에게 건강 관리 부문에서의 첫 번째 영향력 상을 수여했습니다. 밀켄은 밀켄 연구소, 패스터 큐어스 및 전립선 암 재단의 창립자입니다. 이 상은 의료 연구 이니셔티브 지원을 위한 25만 달러의 자선 기부를 포함합니다. 밀켄의 전립선 암 재단은 1993년 이래로 10억 달러 이상을 모금했으며, 28개국의 245개 암 센터에서 2,240개의 연구 프로젝트를 지원하여 전립선 암의 진행에 대한 6개의 신약이 FDA 승인을 받도록 이끌었습니다. 재단의 활동은 지난 20년 동안 전립선 암 사망률 감소에 기여했습니다.
Royalty Pharma (Nasdaq: RPRX) a décerné son premier Prix pour l'Impact dans le secteur de la santé à Michael Milken, fondateur du Milken Institute, de Faster Cures et de la Prostate Cancer Foundation. Ce prix comprend un don caritatif de 250 000 $ pour soutenir des initiatives de recherche médicale. La Prostate Cancer Foundation de Milken a levé plus de 1 milliard de dollars depuis 1993, soutenant 2 240 projets de recherche dans 245 centres de lutte contre le cancer dans 28 pays, ce qui a conduit à l'approbation par la FDA de six nouveaux médicaments pour le cancer de la prostate avancé. Le travail de la fondation a contribué à la diminution des taux de mortalité par cancer de la prostate au cours des deux dernières décennies.
Royalty Pharma (Nasdaq: RPRX) hat seinen ersten Preis für Impact in der Gesundheitsversorgung an Michael Milken, Gründer des Milken Institute, Faster Cures und der Prostate Cancer Foundation, verliehen. Der Preis umfasst eine wohltätige Spende von 250.000 US-Dollar zur Unterstützung von medizinischen Forschungsinitiativen. Die Prostate Cancer Foundation von Milken hat seit 1993 über 1 Milliarde US-Dollar gesammelt und 2.240 Forschungsprojekte in 245 Krebszentren in 28 Ländern unterstützt, was zur FDA-Zulassung von sechs neuen Arzneimitteln für fortgeschrittenen Prostatakrebs geführt hat. Die Arbeit der Stiftung hat zur Senkung der Sterblichkeitsraten bei Prostatakrebs in den letzten zwei Jahrzehnten beigetragen.
- None.
- None.
Insights
This announcement represents a charitable initiative with a relatively minor financial impact of
The news reinforces Royalty Pharma's commitment to healthcare innovation and social responsibility, which could positively influence ESG-focused investors and stakeholder relationships. However, this type of corporate philanthropy, while commendable, typically has material impact on stock performance or financial metrics.
- Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation
- The Prize includes a charitable donation to further fund medical research
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a
“I am delighted to award the inaugural Royalty Pharma Prize for Impact in Healthcare to Michael Milken,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Mike has made a tremendous global impact in the fields of medical research and public health through his work at the Milken institute, Faster Cures and the Prostate Cancer Foundation.”
Michael Milken is the founder and chairman of the Milken Institute, an independent, nonprofit, nonpartisan economic think tank that publishes research and hosts conferences that apply market-based principles and financial innovations to social issues in the US and internationally. Mr. Milken is also the founder of the Prostate Cancer Foundation (PCF). Since its inception in 1993, the PCF has raised over
Royalty Pharma focuses its philanthropy on non-profit institutions and initiatives that enable innovation in life sciences, reduce the risk of disease, and strengthen and ensure equal access to healthcare. In 2022, Royalty Pharma announced a charitable contribution to Icahn Mount Sinai’s Institute for Health Equity Research (IHER) and the creation of the Mount Sinai-Royalty Pharma Alliance for Health Equity Research to support IHER in its ongoing efforts to close the health care disparity gap and translate discoveries into sustainable, scalable initiatives and policies that break down systemic barriers to care among communities in New York City, nationally and globally. Additionally, Royalty Pharma is a founding corporate partner of Life Science Cares New York, which fights poverty and inequity in the city through education. Royalty Pharma has also made charitable contributions to the Leukemia and Lymphoma Society, a global leader in the fight against blood cancer.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the value of Royalty Pharma's (RPRX) inaugural Prize for Impact in Healthcare?
Who received Royalty Pharma's (RPRX) first Prize for Impact in Healthcare in 2024?
How many research projects has the Prostate Cancer Foundation funded through Milken's leadership?
How many new prostate cancer drugs were approved through PCF's support?
